華潤啤酒(00291.HK)擬出資1.5億元參與成立合夥企業
格隆匯 4 月 26日丨華潤啤酒(00291.HK)宣佈,於2021年4月26日,公司全資附屬公司華潤雪花啤酒投資與橫琴潤創、深圳博慧及飛宏築信就成立合夥企業(即潤慧投資(深圳)企業(有限合夥))訂立合夥協議。
合夥企業的全體合夥人認繳出資額之總和為人民幣5億元,其中,華潤雪花啤酒投資、橫琴潤創、深圳博慧及飛宏築信分別出資人民幣1.5億元、人民幣5000萬元、人民幣10萬元及人民幣2.999億元。
合夥企業主要投資的底層資產為(1)華潤雪花啤酒投資的低效資產,包括但不限於因其產能調整停產的工廠的土地使用權及╱或土地上的建築物和設施;及╱或(2)風險控制委員會認可的華潤雪花啤酒投資的其他低效資產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.